{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:52:40Z","timestamp":1785372760819,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The importance of cardio-hemato-oncology programs is increasing. The main aim of the study was to identify all coexisting cardiovascular disorders in patients with new hematological malignancies referred for echocardiography during baseline evaluation before anticancer therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>The study was based on 900 echocardiographic examinations performed within 12 months at the Institute of Hematology and Transfusion Medicine in Poland: 669 tests (74.3%) were dedicated to hemato-oncology patients at the different stages of cancer therapy, however almost a third of the tests (277, 30.8%) were part of a baseline evaluation before starting first line anticancer therapy due to newly diagnosed hematological malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The group of 277 patients with new hematological malignancies (138 women, 49.82%) with a median age of 66 years (interquartile range: 53-72 years) was included in the main analyses. The three most frequent new histopathological diagnoses were: non-Hodgkin lymphoma (63 cases; 22.74%), acute myeloid leukaemia (47 cases; 16.97%), and multiple myeloma (45 cases; 16.25%). The three most common clinical cardiology disorders were arterial hypertension (in 133 patients, 48.01%), arrhythmias (48 patients, 17.33%), and heart failure (39 patients, 14.08%). Among 48 patients with arrhythmias there were 22 cases with atrial fibrillation. The most frequently detected echocardiographic abnormality was Left Atrial Volume Index &amp;gt;34 ml\/m2 which was present in 108 of 277 patients (38.99%) and associated with a significantly greater chance of concomitant diagnosis of arrhythmias (OR=1.98; p=0.048) especially atrial fibrillation (OR=3.39; p=0.025). The second most common echocardiographic finding was diastolic dysfunction 2nd or 3rd degree revealed in 43 patients (15.52%) and associated with a greater chance of simultaneous diagnosis of heart failure (OR=8.32; p&amp;lt;0.0001) or arrhythmias (OR=4.44; p&amp;lt;0.0001) including atrial fibrillation (OR=5.40; p=0.0003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In patients with newly diagnosed hematological malignancies left ventricular diastolic dysfunction is a common abnormality in echocardiography and may determine diagnoses of heart failure or arrhythmias.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1283831","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:41:40Z","timestamp":1706071300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Characteristics of patients with newly diagnosed hematological malignancies referred for echocardiography"],"prefix":"10.3389","volume":"14","author":[{"given":"Jaros\u0142aw","family":"K\u0119pski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Lech-Mara\u0144da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ehjqcco\/qcac070","article-title":"European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment","volume":"9","author":"Lee","year":"2022","journal-title":"Eur Heart J - Qual Care Clin Outcomes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11912-021-01059-1","article-title":"Reaching across the aisle: cardio-oncology advocacy and program building","volume":"23","author":"Sadler","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hfc.2016.12.011","article-title":"How to develop a cardio-oncology clinic","volume":"13","author":"Snipelisky","year":"2017","journal-title":"Heart Failure Clinics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02250-4","article-title":"Current functioning of cardio-oncology units in Spain","volume":"22","author":"Mitroi","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-021-01894-z","article-title":"The Heidelberg cardio-oncology unit (COUNT)-a possible blueprint for improved care of cardio-oncological patients","volume":"111","author":"Lehmann","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.10.005","article-title":"Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology\u2606","volume":"46","author":"Breccia","year":"2019","journal-title":"Semin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11912-018-0725-7","article-title":"Building a cardio-onco-hematology program","volume":"20","author":"Herrmann","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2016.12.041","article-title":"Cardio-onco-hematology in clinical practice. Position paper and recommendations","volume":"70","author":"L\u00f3pez-Fern\u00e1ndez","year":"2017","journal-title":"Rev Espa\u00f1ola Cardiolog\u00eda (English Edition)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the C ardio- O ncology S tudy G roup of the H eart F ailure A ssociation of the E uropean S ociety of C ardiology in collaboration with the I nternational C ardio- O ncology S ociety","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the H eart F ailure A ssociation (HFA), the E uropean A ssociation of C ardiovascular I maging (EACVI) and the Cardio-Oncology C ouncil of the E uropean S ociety of C ardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa034","article-title":"Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry","volume":"29","author":"Caro-Cod\u00f3n","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2071","article-title":"Advanced cancer is also a heart failure syndrome: a hypothesis","volume":"23","author":"Anker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the american society of echocardiography and the european association of cardiovascular imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiography"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2018.06.004","article-title":"Guidelines for performing a comprehensive transthoracic echocardiographic examination in adults: recommendations from the american society of echocardiography","volume":"32","author":"Mitchell","year":"2019","journal-title":"J Am Soc Echocardiography"},{"key":"B15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiography"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.984951","article-title":"Are cardiovascular comorbidities always associated with a worse prognosis in patients with lung cancer","volume":"9","author":"M\u0119drek","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2020.11.020","article-title":"Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC","volume":"74","author":"Mart\u00edn Garc\u00eda","year":"2021","journal-title":"Rev Espa\u00f1ola Cardiolog\u00eda (English Edition)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14082010","article-title":"Baseline electrocardiographic and echocardiographic assessment may help predict survival in lung cancer patients\u2014A prospective cardio-oncology study","volume":"14","author":"M\u0119drek","year":"2022","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11864-021-00850-3","article-title":"Cardiovascular issues in hematopoietic stem cell transplantation (HSCT)","volume":"22","author":"L\u00f3pez-Fern\u00e1ndez","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/echo.14800","article-title":"Focused echocardiography in cardio-oncology","volume":"37","author":"Keramida","year":"2020","journal-title":"Echocardiography"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-10028-1","article-title":"Cardiac imaging in oncology patients in Europe: a model for advancement of CV safety and development of comprehensive CV care","volume":"13","author":"L\u00f3pez-Fern\u00e1ndez","year":"2020","journal-title":"J Cardiovasc Trans Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuab079","article-title":"Cancer and acute cardiovascular diseases: team work to transform the clinical practice","volume":"10","author":"L\u00f3pez-Fern\u00e1ndez","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuac107","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias","volume":"11","author":"Gevaert","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: A scientific statement from the american heart association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.08.009","article-title":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma","volume":"8","author":"Szmit","year":"2014","journal-title":"J Am Soc Hypertension"},{"key":"B30","article-title":"Management of anticoagulation in cancer patients with atrial fibrillation","volume":"24","author":"Szmit","year":"2022","journal-title":"Isr Med Assoc J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2019.03.019","article-title":"Atrial fibrillation in active cancer patients: expert position paper and recommendations","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"2019","journal-title":"Rev Espa\u00f1ola Cardiolog\u00eda (English Edition)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01445-x","article-title":"Cardiac arrhythmias in oncological patients\u2014Epidemiology, risk factors, and management within the context of the new ESC 2022 guidelines","volume":"25","author":"Gawlik","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2021.100830","article-title":"Elevated resting heart rate is a marker of subclinical left ventricular dysfunction in hodgkin lymphoma survivors","volume":"35","author":"Heemelaar","year":"2021","journal-title":"IJC Heart Vasculature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001216","article-title":"Chemotherapy induced arrhythmias","volume":"80","author":"Essa","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa037","article-title":"Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database","volume":"7","author":"Alexandre","year":"2021","journal-title":"Eur Heart J - Cardiovasc Pharmacotherapy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.11.019","article-title":"Atrial fibrillation incidence associated with exposure to anticancer drugs used as monotherapy in clinical trials","volume":"5","author":"Alexandre","year":"2023","journal-title":"JACC: CardioOncology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13960","article-title":"Trends and in-hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002\u20132019)","volume":"110","author":"Ammad Ud Din","year":"2023","journal-title":"Eur J Haematology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.11.038","article-title":"Impact of atrial fibrillation on heart failure in patients treated with anthracycline chemotherapy","volume":"211","author":"Onoue","year":"2024","journal-title":"Am J Cardiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.12.002","article-title":"From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction","volume":"4","author":"Minotti","year":"2022","journal-title":"JACC: CardioOncology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0500","article-title":"Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors","volume":"20","author":"Serrano","year":"2015","journal-title":"Oncologist"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/echo.15012","article-title":"Diastolic function as an early marker for systolic dysfunction and all-cause mortality among cancer patients","volume":"38","author":"Arnold","year":"2021","journal-title":"Echocardiography"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1283831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:41:43Z","timestamp":1706071303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1283831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":41,"alternative-id":["10.3389\/fonc.2024.1283831"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1283831","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"article-number":"1283831"}}